Answer to Question 1
1
Rationale 1: There is an increased incidence of atypical fractures associated with bisphosphonate use. Thigh or groin pain has been noted to occur prior to fracture.
Rationale 2: Nausea may occur if the patient is on a vitamin D supplement, but this is not the priority.
Rationale 3: Headache may occur if the patient is on a vitamin D supplement, but this is not the priority.
Rationale 4: Skin eruptions are not an effect of bisphosphonate use.
Global Rationale: There is an increased incidence of atypical fractures associated with bisphosphonate use. Thigh or groin pain has been noted to occur prior to fracture. Nausea or headache may occur if the patient is on a vitamin D supplement, but this is not the priority. Skin eruptions are not an effect of bisphosphonate use.
Answer to Question 2
1, 2, 4
Rationale 1: Opioid blockers inhibit both the mu and kappa receptors.
Rationale 2: Some opioids stimulate a particular receptor; others block a receptor.
Rationale 3: Opioid blockers inhibit both the mu and kappa receptors.
Rationale 4: Opioids interact with at least six types of receptors: mu (types one and two), kappa, delta, and nociceptin.
Rationale 5: Opioids interact with at least four types of receptors: mu (types one and two), kappa, delta, and nociceptin.
Global Rationale: Opioid blockers inhibit both the mu and kappa receptors. Some opioids stimulate a particular receptor; others block a receptor. Opioids interact with at least four types of receptors: mu (types one and two), kappa, delta, and nociceptin.
Nurse examining and measuring hematuria sample from client with a UTI
Patient teaching: vascular assessment
Patient Education Follow-up Plan
Muscle weakness caused by myasthenia gravis is evident in the eyes of this patient.
Drugs Used in the Treatment of Ulcerative Colitis
National Patient Safety Goals for Acute-Care Hospitals